Trials / Recruiting
RecruitingNCT06958536
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 99 (estimated)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SAR442970 | Route of Administration: Subcutaneous |
| DRUG | Placebo | Route of Administration: Subcutaneous |
Timeline
- Start date
- 2025-06-03
- Primary completion
- 2026-12-17
- Completion
- 2029-10-17
- First posted
- 2025-05-06
- Last updated
- 2026-03-27
Locations
66 sites across 12 countries: United States, Australia, Belgium, China, Czechia, France, Germany, Japan, Poland, South Africa, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06958536. Inclusion in this directory is not an endorsement.